Human Clinical Evidence for Kisspeptin-10
Current guidelines recommend against using kisspeptin for treating infertility in functional hypothalamic amenorrhea (FHA), as the evidence remains insufficient for clinical use despite promising early research 1.
Guideline Position
The 2017 Endocrine Society Clinical Practice Guideline on Functional Hypothalamic Amenorrhea explicitly states a recommendation against the use of kisspeptin and leptin for treating infertility (weak recommendation, very low-quality evidence) 1. The guideline acknowledges that researchers have investigated kisspeptin as a possible modality for restoring LH pulsatility and gonadal function in women with FHA, but emphasizes that more research is needed on therapeutic uses of kisspeptin, which is not yet clinically available 1.
Research Evidence on Efficacy
In Women
The clinical evidence shows marked sexual dimorphism in kisspeptin-10 responses:
Follicular phase women: Kisspeptin-10 failed to stimulate gonadotropin release at doses up to 10 nmol/kg IV bolus, 32 nmol/kg subcutaneous, or 720 pmol/kg/min IV infusion 2
Preovulatory phase women: IV bolus kisspeptin-10 (10 nmol/kg) successfully elevated LH and FSH 2
Postmenopausal women: Demonstrated the largest gonadotropin responses to kisspeptin-10 (0.3 µg/kg), with significantly greater LH and FSH increases compared to other groups 3
Women on combined oral contraceptives: No LH stimulation observed, suggesting pharmacological estrogen/progestogen suppresses kisspeptin responsiveness 3
Women on progestogen-only contraceptives: Maintained LH response to kisspeptin-10 3
Early research in FHA showed that kisspeptin-54 (not kisspeptin-10) administered via constant 10-hour infusion at variable doses increased LH pulsatility in all five women studied without desensitization 1. However, this remains experimental.
In Men
Kisspeptin-10 demonstrates robust and consistent efficacy in healthy men:
Acute dosing: IV bolus doses as low as 0.3 nmol/kg stimulate LH, with maximal response at 1.0 µg/kg (LH increased from 4.1 to 12.4 IU/L at 30 minutes) 4. Doses of 3 µg/kg showed reduced response, suggesting a bell-shaped dose-response curve 4
Chronic administration: Daily 8-hour subcutaneous infusions (150 nmol/h) sustained gonadotropin increases for 12 days without desensitization. Mean LH remained elevated (day 1: +1.68 IU/L; day 12: +1.14 IU/L vs vehicle) 5. The kisspeptin receptor remained functional after 12 days, as demonstrated by preserved response to bolus dosing 5
LH pulse dynamics: Continuous infusion at 1.5 µg/kg/h increased LH pulse frequency from 0.7 to 1.0 pulses/hour and increased secretory burst mass from 3.9 to 12.8 IU/L 4
Testosterone effects: Chronic administration increased testosterone from 16.6 to 24.0 nmol/L 4, and from 8.5 to 11.4 nmol/L in men with type 2 diabetes 6
In Type 2 Diabetes with Hypogonadism
In five hypotestosteronemic men with type 2 diabetes, kisspeptin-10 (4 µg/kg/h infusion for 11 hours) increased LH from 3.9 to 20.7 IU/L and testosterone from 8.5 to 11.4 nmol/L, with increased LH pulse frequency from 0.6 to 0.9 pulses/hour 6. This suggests potential therapeutic utility in central hypogonadism.
Novel Intranasal Route
Recent 2025 data demonstrates that intranasal kisspeptin-54 (not kisspeptin-10) at 12.8 nmol/kg rapidly stimulates gonadotropins in healthy men (mean LH increase 4.4 IU/L), healthy women (1.4 IU/L), and women with hypothalamic amenorrhea (4.4 IU/L) 7. This non-invasive route shows promise but requires further validation.
Safety Profile
Clinical Trial Safety
Across all human studies reviewed, no serious adverse events or side effects were reported with kisspeptin-10 administration via IV or subcutaneous routes 5, 6, 3, 2, 4. The intranasal kisspeptin-54 study specifically noted "without any side effects or adverse events encountered" 7.
Important Caveats
Desensitization concerns: Continuous 5-day infusion at 180 nmol/h resulted in gonadotropin levels returning to baseline despite sustained testosterone elevation, suggesting tachyphylaxis with continuous exposure 5. However, intermittent daily dosing (8 hours on, 16 hours off) avoided this desensitization 5
Dose-response complexity: The bell-shaped dose-response curve in men (reduced response at 3 µg/kg vs 1 µg/kg) indicates careful dose titration is necessary 4
Sex steroid dependency: The gonadotropin response is heavily modulated by prevailing sex steroid milieu, with enhanced responses in low-estrogen states and suppressed responses with pharmacological estrogen 3
Clinical Implications
Kisspeptin-10 is not approved for clinical use and should not be prescribed outside of research protocols. The FDA drug label information provided 8 appears to describe a homeopathic product for allergy symptoms, which is entirely unrelated to the reproductive hormone effects of kisspeptin-10 studied in clinical trials.
The evidence demonstrates proof-of-concept that kisspeptin can stimulate the reproductive axis, particularly in men and in specific hormonal contexts in women. However, the Endocrine Society's recommendation against its use for infertility treatment reflects the reality that:
- No long-term efficacy or safety data exists
- Optimal dosing regimens remain undefined
- The peptide is not commercially available for therapeutic use
- Alternative established therapies (pulsatile GnRH, gonadotropins) have superior evidence bases 1
The sexual dimorphism in response patterns means that any future therapeutic development must account for menstrual cycle phase and sex steroid status when treating women 2.